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Abstract
Human immunodeficiency virus (HIV-1) enters cells following sequential activation of the high-potential-energy viral
envelope glycoprotein trimer by target cell CD4 and coreceptor. HIV-1 variants differ in their requirements for CD4; viruses
that can infect coreceptor-expressing cells that lack CD4 have been generated in the laboratory. These CD4-independent
HIV-1 variants are sensitive to neutralization by multiple antibodies that recognize different envelope glycoprotein epitopes.
The mechanisms underlying CD4 independence, global sensitivity to neutralization and the association between them are
still unclear. By studying HIV-1 variants that differ in requirements for CD4, we investigated the contribution of CD4 binding
to virus entry. CD4 engagement exposes the coreceptor-binding site and increases the ‘‘intrinsic reactivity’’ of the envelope
glycoproteins; intrinsic reactivity describes the propensity of the envelope glycoproteins to negotiate transitions to lower-
energy states upon stimulation. Coreceptor-binding site exposure and increased intrinsic reactivity promote formation/
exposure of the HR1 coiled coil on the gp41 transmembrane glycoprotein and allow virus entry upon coreceptor binding.
Intrinsic reactivity also dictates the global sensitivity of HIV-1 to perturbations such as exposure to cold and the binding of
antibodies and small molecules. Accordingly, CD4 independence of HIV-1 was accompanied by increased susceptibility to
inactivation by these factors. We investigated the role of intrinsic reactivity in determining the sensitivity of primary HIV-1
isolates to inhibition. Relative to the more common neutralization-resistant (‘‘Tier 2-like’’) viruses, globally sensitive (‘‘Tier 1’’)
viruses exhibited increased intrinsic reactivity, i.e., were inactivated more efficiently by cold exposure or by a given level of
antibody binding to the envelope glycoprotein trimer. Virus sensitivity to neutralization was dictated both by the efficiency
of inhibitor/antibody binding to the envelope glycoprotein trimer and by envelope glycoprotein reactivity to the inhibitor/
antibody binding event. Quantitative differences in intrinsic reactivity contribute to HIV-1 strain variability in global
susceptibility to neutralization and explain the long-observed relationship between increased inhibitor sensitivity and
decreased entry requirements for target cell CD4.
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Introduction
The entry of human immunodeficiency virus type 1 (HIV-1)
into cells is mediated by the envelope glycoprotein complex on the
viral membrane [1]. This complex is a trimer of heterodimeric
subunits, each composed of a gp120 surface glycoprotein and a
gp41 transmembrane glycoprotein [2]. In their unliganded form,
the HIV-1 envelope glycoproteins exist in a high-potential-energy
state. Binding to the receptors on the target cell triggers
conformational changes in the envelope glycoproteins that lead
to lower-energy states and activate the entry pathway [3,4,5].
Entry of most HIV-1 strains into cells is initiated by interaction
of gp120 with the primary receptor, CD4, on the cell surface [6,7].
The CD4-gp120 interaction induces significant conformational
changes in the HIV-1 envelope glycoproteins [2,3]. CD4 binding
increases the ability of gp120 to engage the coreceptor, either
CCR5 or CXCR4 [8,9]. CD4 binding also induces the pre-
hairpin intermediate, an envelope glycoprotein structure contain-
ing a trimeric coiled coil formed by the gp41 heptad repeat 1
(HR1) regions [10,11,12]. Subsequent binding of coreceptor to this
CD4-activated intermediate leads to the formation of an
energetically stable six-helix bundle, in which three gp41 heptad
repeat 2 (HR2) helices interact with the HR1 coiled coil. During
the process of receptor binding, the hydrophobic ‘‘fusion peptide’’
at the gp41 N-terminus is thought to penetrate into the target cell
membrane [13,14,15]. As a result, the gp41 N-terminus and the
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membranes, respectively, and formation of the six-helix bundle
thus approximates and fuses these membranes [11,16,17].
For most HIV-1 strains, CD4 is an obligate receptor. However,
some naturally-occurring HIV-1 strains can replicate in cell types,
like tissue macrophages or brain microglia, that express only low
levels of CD4 [18]. Moreover, CD4-independent HIV-1 strains
have been derived by virus passage on CD4-negative, coreceptor-
positive cells in tissue culture [19,20,21,22]. Despite the potentially
advantageous broadening of tropism associated with a lower
dependence on CD4 for infection, HIV-1 strains that are fully
independent of CD4 have been identified only rarely in infected
people [23,24]. By contrast, CD4-independent strains of HIV-2
and simian immunodeficiency virus (SIV) are more commonly
encountered in vivo, particularly in body compartments like the
brain where cells expressing high levels of CD4 are limited in
number [25,26,27,28].
Studies of primate immunodeficiency virus variants have
provided clues to the mechanism of CD4 independence and the
balancing selection that operates on these viruses in vivo. Even in
the absence of CD4, CD4-independent envelope glycoproteins can
bind the coreceptor or antibodies that recognize ‘‘CD4-induced’’
gp120 epitopes overlapping the coreceptor-binding site (CoR-BS)
[19,20]. As expected, some of the sequence changes associated
with acquisition of CD4 independence involve the CoR-BS itself
(the V3 loop and b19 strand of gp120) or increase its exposure or
formation (for example, by repositioning the V1/V2 loops that
mask the coreceptor-binding region) [21,29]. However, changes
associated with CD4 independence have also been observed in
envelope glycoprotein elements, including gp41, that are not
directly involved in coreceptor binding [20,22,30]. How these
changes influence viral dependence on CD4 is poorly understood.
Interestingly, most HIV-1, HIV-2 and SIV variants that are
CD4-independent also exhibit an increased sensitivity to neutral-
ization by multiple antibodies directed against different envelope
glycoprotein epitopes [30,31,32,33,34]. Increased exposure of the
CoR-BS may explain the increased sensitivity to antibodies that
recognize CD4-induced or V3 gp120 epitopes, which overlap the
CoR-BS [20,22,31,32]. However, CD4-independent viruses also
exhibit sensitivity to neutralization by antibodies that recognize
epitopes not associated with coreceptor binding, such as the anti-
gp41 antibody 2F5 and the 2G12 antibody, which recognizes
gp120 glycans [30,31]. For the latter epitopes, antibody binding to
the envelope glycoprotein trimer has not demonstrated a
consistent correlation with neutralization sensitivity or CD4
dependence [31,33].
Generalized (global) changes in sensitivity to antibodies are not
limited to CD4-independent viruses. In vitro adaptation of HIV-1
to replicate in tissue-cultured cells, in the absence of immune
selective pressure, is often associated with an increase in sensitivity
to multiple antibodies that target a wide range of envelope
glycoprotein epitopes [35,36,37,38,39,40,41,42]. In several in-
stances, a limited number of sequence changes are associated with
the generalized increase in sensitivity [32,39,40]. As observed for
the neutralization-sensitive CD4-independent viruses, altered
epitope integrity or exposure on the envelope glycoprotein trimer
is not the sole explanation of the different sensitivity of HIV-1
variants to antibody neutralization.
To understand more clearly the role of CD4 in HIV-1
infection, we investigated the contribution of envelope glycopro-
tein changes to the CD4 independence and neutralization
sensitivity of an HIV-1 variant selected to replicate in
CD4
2CCR5
+ cells [19]. Several changes in the ectodomain of
the gp41 transmembrane envelope glycoprotein were found to
contribute to CD4 independence, even though they exerted little
effect on CoR-BS exposure. These gp41 changes also contributed
to the sensitivity of the envelope glycoprotein complex to a
variety of perturbations (binding of antibodies and small
molecules, exposure to cold). Thus, we propose that these gp41
changes modulate a previously unrecognized property of the
HIV-1 envelope glycoproteins that we designate ‘‘intrinsic
reactivity’’. Intrinsic reactivity describes the propensity of the
envelope glycoproteins to negotiate the transition to another state
upon stimulation by ligand binding or incubation on ice. Our
findings indicate that intrinsic reactivity and CoR-BS exposure
both contribute to the formation/ exposure of the gp41 HR1
coiled coil, a structural change that is tightly correlated with CD4
independence. Furthermore, our results from a large panel of
primary HIV-1 isolates suggest that intrinsic reactivity modulates
the level of virus susceptibility to antibody-mediated neutraliza-
tion. Thus, both coreceptor responsiveness and inhibitor
sensitivity of HIV-1 are determined not only by the binding
affinity of the relevant ligand, but by the reactivity of the
envelope glycoprotein complex to the bound ligand.
Results
Determinants of CD4 Independence in the ADA/HXBc2
Chimeric Envelope Glycoproteins
The transition from CD4-dependent to CD4-independent HIV-
1 typically involves multiple changes in gp120 and/or gp41
[21,22,29,30]. However, in one case, the loss of a single
glycosylation site due to an N197S change in the V1/V2 stem
of gp120 was sufficient to generate a CD4-independent,
neutralization-sensitive HIV-1 ADA variant [19]. This change
increased the binding of unliganded gp120 both to CCR5 and to
antibodies that recognize CD4-induced epitopes overlapping the
CoR-BS [19]. The absence of a glycan at asparagine 197 was
suggested to alter the conformation of the V1/V2 loops, which
mask the CoR-BS [43]. In support of this model, deletion of the
gp120 V1/V2 loops in either HIV-1 or SIV resulted in a CD4-
independent phenotype [43,44].
Author Summary
Human immunodeficiency virus (HIV-1), the cause of
acquired immunodeficiency syndrome (AIDS), enters cells
by attaching its major surface component, the envelope
glycoprotein spike, to a receptor protein on the target cell
called CD4. This attachment promotes cell entry by
allowing the envelope protein to bind a second receptor
(the ‘‘coreceptor’’) on the cell. In rare cases, the virus is pre-
activated and can bind coreceptor and enter cells in the
absence of CD4. Such viruses, which are rarely found in
patients, are also very sensitive to inhibition by antibodies
made by the host immune system. We describe here a new
property of HIV-1 called ‘‘intrinsic reactivity’’ that regulates
the level of both entry into cells and sensitivity to
antibodies. Intrinsic reactivity dictates the level of respon-
siveness of the envelope protein to the binding of
stimulatory (coreceptor) and inhibitory (antibody) agents.
Increases in intrinsic reactivity also result in enhanced
sensitivity to inactivation at cold temperatures, which
serves as a quantitative surrogate for intrinsic reactivity. In
human hosts, HIV-1 must regulate its intrinsic reactivity to
balance the ability to enter cells expressing low levels of
CD4 with the requirement to avoid the host antibody
response.
Reactivity of HIV-1 Envelope Glycoproteins
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did not result in CD4 independence [19]. We hypothesized that
particular sequence elements in the envelope glycoprotein of the
parental virus allowed the N197S mutant to replicate in
CD4
2CCR5
+ cells. The ADA/Hx envelope glycoproteins used
in the original study [19] are chimeric, with gp120 and the N-
terminal part of the gp41 ectodomain derived from the CCR5-
tropic ADA strain and the C-terminal part of gp41 derived from
the CXCR4-tropic HXBc2 strain (Figure 1). To investigate the
potential contribution of the HXBc2-derived gp41 sequences to
CD4 independence, HIV-1 envelope glycoproteins that have the
chimeric ADA/Hx gp41 ectodomain, the N197S change in
gp120, or both modifications were tested for the ability to support
virus entry into CD4
+CCR5
+ and CD4
2CCR5
+ cells. We
compared the original ADA/Hx [19] with a new set of constructs
made from the AD8 strain, which was molecularly cloned from the
AD-87 derivative of ADA and closely resembles ADA in sequence
(See Materials and Methods for details). Both the N197S change
and the HXBc2-derived gp41 sequences (labeled J1Hx) increased
the relative CD4-independent infectivity of the virus to a similar
extent (Figure 1 and Figure S1A). Introduction of both changes
exerted an even greater effect on infection of CD4
2CCR5
+ cells,
allowing a level of infection comparable to that of the ADA/Hx
envelope glycoproteins with the N197S change. Apparently, both
the N197S and the gp41 changes in the ADA/Hx 197 envelope
glycoproteins contribute to CD4 independence.
We then examined the capacity of soluble gp120 shed from
envelope glycoprotein-expressing cells to bind human CCR5 in
the absence of CD4 (Figure 2A). As shown previously [19,43], the
N197S change increased CCR5 binding. The presence of the
HXBc2-derived gp41 sequences did not affect the binding of shed
gp120 to CCR5.
Exposure of the CoR-BS on the cell surface-expressed envelope
glycoprotein trimer was measured using the 412d antibody, which
mimics the N-terminus of CCR5 and recognizes a CD4-induced
gp120 epitope [45,46]. Binding was measured using a cell-based
ELISA system [47] and normalized for envelope glycoprotein cell
surface expression by comparison with the binding of the 2G12
antibody, which recognizes a gp120 carbohydrate epitope that is
not involved in receptor engagement [48]. The binding of 412d to
the envelope glycoprotein trimer was significantly increased by the
N197S change, but was only slightly affected by the J1Hx gp41
changes (Figure 2B). These data indicate that the N197S change is
sufficient for spontaneous exposure of the CCR5-binding site;
however, both the N197S change and the HXBc2-derived gp41
sequences contribute to CD4-independent infection. Apparently,
an envelope glycoprotein property that is distinct from CCR5
binding and contributes to infection of CD4
2CCR5
+ cells is
specified by the gp41 sequences.
Identification of the HXBc2-derived gp41 Sequence
Elements that Contribute to CD4 Independence
To identify the HXBc2-derived sequence elements that impart
CD4 independence to the J1Hx(197) chimera, we studied chimeric
envelope glycoproteins that contain different portions of the
HXBc2 gp41 ectodomain (See J1Hx(197), J2Hx(197), and
J3Hx(197) in Figure 1). Reduction of the size of the gp41
ectodomain segment contributed by HXBc2 and replacement with
the corresponding AD8 sequence resulted in a decreased capacity
to infect CD4
2CCR5
+ cells (Figures 1 and S1A). The level of
CD4-independent infection mediated by the J3Hx(197) construct
was similar to that observed for the AD8(197) variant. These
observations suggest that HXBc2 sequences in the gp41
ectodomain must contribute to the ability of the chimeric envelope
glycoproteins to support CD4-independent infection.
Several AD8 amino acid residues in the implicated gp41
ectodomain segment were altered to the corresponding HXBc2
residues. We thus identified two changes (NM625/626HT and
D674N (hereafter designated HT and N, respectively)) that
significantly contribute to the capacity to infect CD4
2CCR5
+
cells (Figure 1 and Figure S1A). In the context of the J3Hx(197)
envelope glycoproteins, the HT and N changes additively
Figure 1. Identification of determinants of CD4 independence. Schematic representation of the chimeric envelope glycoprotein variants
used in this study. Sequences derived from the ADA, HXBc2 and AD8 strains are represented by striped, black and white boxes, respectively. The
infection of CD4
2CCR5
+ and CD4
+CCR5
+cells by 25,000 RT units of virus containing each envelope glycoprotein variant was measured. The relative
CD4-independent infectivity of each envelope glycoprotein (6 standard error of the mean, SEM) is defined as the level of infection of CD4
2CCR5
+
cells divided by that of CD4
+CCR5
+ cells.
doi:10.1371/journal.ppat.1002101.g001
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S1A), together explaining most of the contribution of the HXBc2
ectodomain sequences to this phenotype. Similarly, the HT and N
changes contributed to CD4-independent infection when intro-
duced into the AD8(197) envelope glycoproteins (data not shown).
No effects of the N197S or gp41 changes on the efficiency of
gp160 envelope glycoprotein precursor processing, cell-surface
expression level or virion incorporation that correlated with CD4
independence were observed (Figures S1B and S1C). However,
the CD4 independence of the envelope glycoprotein variants
strongly correlated with the binding of the 17b, 48d and 412d
antibodies, which are directed against CD4-induced gp120
epitopes [49], to the unliganded cell surface-expressed envelope
glycoproteins (Figure 2C). By contrast, recognition and neutrali-
zation by the PG16 antibody, which preferentially binds the
unliganded envelope glycoprotein trimer [50], were decreased for
the more CD4-independent envelope glycoproteins (Figure S2).
These results suggest that CD4-independent envelope glycoprotein
trimers spontaneously sample conformations distinct from the
unliganded state and closer to the CD4-bound state.
We examined the effects of the above gp41 changes in
combination with deletion of the V1/V2 loops. Removal of the
V1/V2 loops increased infection of CD4
2CCR5
+ cells and
decreased infection of CD4
+CCR5
+ cells (Figure S3), similar to
the effect of the N197S change. The HXBc2 gp41 ectodomain
sequences contributed to the efficiency with which the V1/V2-
deleted envelope glycoproteins supported entry into CD4
2CCR5
+
cells (compare AD8(DV) and J1Hx(DV) in Figure S3). The HT
and N changes in gp41 also increased the relative CD4
independence of the J3Hx(DV) construct, but to a lesser extent
than that observed for the J3Hx(197) envelope glycoproteins.
In summary, an HIV-1 envelope glycoprotein function specified
by a small number of amino acid residues in the HxBc2 gp41
ectodomain contributes, along with increased exposure of the
CoR-BS in gp120, to infection of CD4
2CCR5
+ cells.
Spontaneous Formation/Exposure of the HR1 Coiled Coil
in CD4-independent Envelope Glycoproteins
Binding of CD4 to the HIV-1 envelope glycoproteins results in
the formation/exposure of two functionally significant structures: i)
the CoR-BS on gp120, and ii) the gp41 HR1 coiled coil
[49,51,52,53,54,55]. CD4-independent envelope glycoproteins
exhibit increased exposure of the CoR-BS [20,30,31,34,43,44],
but the state of gp41 in these envelope glycoproteins is not
understood. We examined the formation/exposure of the HR1
coiled coil in our panel of envelope glycoprotein variants by using
the C34-Ig molecule, which is composed of an IgG1 Fc region
linked to the C34 peptide [53]. The C34 peptide corresponds to
Figure 2. Epitope exposure on CD4-independent envelope glycoproteins. (A) Binding of radiolabeled wild-type and mutant gp120 to
CD4
2CCR5
+ Cf2Th cells. Following incubation of equivalent amounts of radiolabeled gp120 from the indicated HIV-1 envelope glycoprotein variants
with CD4
2CCR5
+ cells at 37uC, the cells were washed and lysed. The lysates were used for immunoprecipitation of gp120, which was quantitated by
densitometry. Data are presented as relative radioactivity units (RU). (B) Binding of the 412d antibody (1 mg/ml) to COS-1 cells that transiently express
the indicated envelope glycoproteins at 37uC. The binding of 412d was normalized to that of a control anti-gp120 antibody, 2G12. (C) Relationship
between the binding of antibodies and sCD4 to the cell surface-expressed envelope glycoproteins and the relative CD4-independent infectivity of
each variant. The Spearman rank-order correlation coefficient is indicated (*, P,0.05).
doi:10.1371/journal.ppat.1002101.g002
Reactivity of HIV-1 Envelope Glycoproteins
PLoS Pathogens | www.plospathogens.org 4 June 2011 | Volume 7 | Issue 6 | e1002101the gp41 HR2 region, which interacts with the HR1 coiled coil to
form the six-helix bundle [16,17]. To facilitate detection of bound
C34-Ig, cell-surface expression levels of the HIV-1 envelope
glycoproteins were increased by deletion of the cytoplasmic tail of
gp41, which contains an endocytosis signal [56,57]. Removal of
the cytoplasmic tail did not detectably affect the conformation of
the CD4-dependent AD8 envelope glycoproteins, and slightly
increased the formation/exposure of the already-exposed CD4-
induced epitopes on the highly CD4-independent envelope
glycoproteins (Table S1). Furthermore, cytoplasmic tail deletion
did not alter the relative ability of the different HIV-1 envelope
glycoprotein variants to infect CD4
2CCR5
+ cells (Figure S4A).
Binding of C34-Ig to COS-1 cells that express the panel of
mutant HIV-1 envelope glycoproteins was measured using the
cell-based ELISA method [47]. Because binding of C34-Ig to the
HIV-1 envelope glycoproteins is reduced at higher temperatures
(Figure S4B), all binding assays were performed at temperatures
below 26uC. Minimal C34-Ig binding to the unliganded AD8
envelope glycoproteins was detected, whereas treatment with
sCD4 significantly increased C34-Ig binding, as expected
(Figure 3A and B, and ref. [47]). Surprisingly, for the envelope
glycoproteins with either the N197S change or the gp41 changes,
C34-Ig binding could be detected even in the absence of sCD4,
and was further increased by sCD4 treatment (Figure 3A–C). The
envelope glycoprotein variants with both N197S and gp41
changes exhibited the highest levels of spontaneous C34-Ig
binding in the absence of sCD4. The degree of C34-Ig binding
to the envelope glycoprotein variants in the absence of sCD4
strongly correlated with the ability of the envelope glycoproteins to
mediate infection of CD4
2CCR5
+ cells (Figure 3C, right panel).
Thus, both the N197S change and the gp41 changes contribute to
the formation/exposure of the HR1 coiled coil on gp41, which in
turn promotes the infection of CD4-negative cells expressing
CCR5.
We also studied C34-Ig binding to the panel of envelope
glycoprotein variants with a deletion of the V1/V2 variable loops.
V1/V2 loop deletion, even in the absence of any gp41 changes,
induced an increase in C34-Ig binding far greater than that
associated with the N197S or the gp41 changes (Figure 3D and
Figure S4, C and D). C34-Ig binding to the unliganded V1/V2
loop-deleted envelope glycoproteins ranged from 20–45% of that
seen after sCD4 treatment. Again, a good correlation was
observed between C34-Ig binding to the unliganded envelope
glycoproteins and the ability to mediate infection of CD4
2CCR5
+
cells (Figure 3D, right panel). This observation further supports the
importance of formation/exposure of the gp41 HR1 coiled coil to
the infection pathway for CD4
2CCR5
+ cells.
We also examined the effect of two previously characterized
[58,59] gp120 changes, S375W and H66N, on the binding of
C34-Ig to the HIV-1 envelope glycoproteins. The S375W change
increases the spontaneous sampling of the CD4-bound conforma-
tion by the HIV-1 gp120 glycoprotein, and modestly increases the
formation/exposure of the CoR-BS [59]. The S375W change had
no significant effect on the formation/exposure of the HR1 coiled
coil (Figures 3E and S5B) and did not increase the ability of HIV-1
to infect CD4
2 cells [see below and reference [59]. The H66N
change has been shown to decrease the spontaneous exposure of
the CoR-BS on the ADA/Hx(197) envelope glycoproteins [58].
The H66N change reduced the efficiency of CD4-independent
infection mediated by both the ADA/Hx(197) and J1Hx(197)
envelope glycoproteins ([58] and Figure S5A, respectively). The
H66N change significantly reduced C34-Ig binding to the
unliganded J1Hx(197) and AD8(DV) envelope glycoproteins
(Figures 3E and S5B). These observations support the correlation
between the ability of the HIV-1 envelope glycoproteins to
mediate CD4-independent infection and spontaneous formation/
exposure of the gp41 HR1 coiled coil.
Binding of sCD4 to the HIV-1 envelope glycoproteins induces a
short-lived activated state, characterized by transient exposure of
the HR1 coiled coil that coincides with a transient capacity to
infect CD4
2CCR5
+ cells [47]. We examined how long after a
sCD4 pulse the envelope glycoproteins remained competent for
C34-Ig binding at 37uC. For the more CD4-independent envelope
glycoproteins, the CD4-induced intermediates capable of binding
C34-Ig exhibited longer half-lives (Figure S5C).
To learn whether the HR1 coiled coil is exposed on the
unliganded envelope glycoproteins of other CD4-independent
HIV-1 strains, we measured binding of C34-Ig to HIV-1 8x, a
CXCR4-tropic, CD4-independent variant that was derived from
the CD4-dependent HIV-1 IIIB strain [20]. As was observed for
CD4-independent variants of the AD8 strain, the HIV-1 8x
envelope glycoproteins bound C34-Ig in the absence of sCD4
(Figure 3F). By contrast, C34-Ig binding to the HXBc2 envelope
glycoproteins, a CD4-dependent clone of the HIV-1 IIIB strain,
required sCD4 addition (Figure S4D).
Thus, unliganded CD4-independent HIV-1 envelope glycopro-
teins are more prone to sample conformations that resemble the
CD4-bound state, in which the HR1 coiled coil is formed and
exposed. The spontaneous formation/exposure of this gp41
structure strongly correlates with the ability of the HIV-1 envelope
glycoproteins to infect CD4-negative cells expressing CCR5.
A Globally Inhibitor-sensitive State Is Induced by Specific
Envelope Glycoprotein Changes Associated with CD4
Independence
Relative to the parental strains, many CD4-independent HIV-1
isolates exhibit an increased sensitivity to neutralization by
antibodies [30,31,32]. The defined gradation of CD4 indepen-
dence in our panel of AD8 variants provided an opportunity to
examine the potential relationships between CD4 independence
and sensitivity to neutralization by different antibodies and
inhibitory ligands.
Regardless of the target epitope or inhibitor used, a similar
general pattern of sensitivity to inhibition was observed (Figure 4,
A–E and Figure S6). Viruses with the J1Hx(197) envelope
glycoproteins were highly sensitive to multiple different inhibitory
ligands compared with viruses containing the AD8 envelope
glycoproteins. The N197S and gp41 changes cooperatively
increased sensitivity to all inhibitors tested, regardless of the target
epitope. The HT and N changes in gp41, either individually or
together, positively affected this global neutralization sensitivity.
The gp41 changes also exerted specific effects on neutralization by
the gp41-directed 2F5 antibody; these local effects slightly
perturbed the rank order of sensitivity of the envelope glycoprotein
variants to this antibody. Despite these occasional epitope-specific
effects, statistically significant correlations were observed between
the level of CD4 independence of each envelope glycoprotein
variant and sensitivity to inhibition by most of the ligands tested
(Figure 4F). Of note, this correlation also applies to JRC-II-191, a
356-Dalton CD4-mimetic compound.
HIV-1 has evolved steric and thermodynamic constraints on the
binding of antibodies to the CD4-binding site (CD4BS) of gp120
[60,61]. Thus, most CD4BS antibodies, like F105, b6 and b13,
bind envelope glycoprotein trimers inefficiently and neutralize
HIV-1 only weakly. Based on x-ray structures of Fab complexes
with monomeric gp120 cores, the target epitopes and approach
angles of these weak CD4BS antibodies differ only subtly from
those of the potent and broad CD4BS antibody, b12, which
Reactivity of HIV-1 Envelope Glycoproteins
PLoS Pathogens | www.plospathogens.org 5 June 2011 | Volume 7 | Issue 6 | e1002101Figure 3. Relationship between spontaneous formation/exposure of the gp41 HR1 coiled coil and CD4 independence. (A,B) COS-1
cells that transiently express the indicated cytoplasmic tail-deleted envelope glycoproteins were incubated with 34 Ig(30 mg/ml) at 16uC for 30 min in
the absence (A) or presence (B) of sCD4 (20 mg/ml). Data represent mean C34-Ig binding (6 SEM) after subtracting the background binding of C34-Ig
to mock-transfected cells. (C, left) Relative CD4-independent binding of C34-Ig, defined as the level of C34-Ig binding in the absence of sCD4
expressed as the percentage of C34-Ig binding in the presence of sCD4 for the panel of cytoplasmic tail- deleted envelope glycoprotein variants that
combine the N197S mutation with the gp41 changes. (C, right) Correlation between relative CD4-independent infectivity mediated by the envelope
glycoprotein variants and their relative CD4-independent binding of C34-Ig. The Spearman rank-order correlation coefficient is indicated (*, P,0.05).
(D, left) Relative CD4-independent C34-Ig binding to cells expressing cytoplasmic tail-deleted envelope glycoprotein variants that combine a deletion
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change alone significantly decreased HIV-1 neutralization by the
b12 antibody (Figure S6F); this result is consistent with previous
observations that alterations in the gp120 V1/V2 loops can
decrease HIV-1 sensitivity to b12 neutralization [36]. Because of
the apparently local effects of the N197S change on envelope
glycoprotein recognition by the b12 antibody, we compared the
effect of the gp41 changes alone on virus neutralization by the
above CD4BS antibodies. The sensitivity of HIV-1 to the b13, b6,
F105 and b12 antibodies was enhanced by the gp41 changes
(Figure 5 and Figure S6G). Of the different CD4BS antibodies, the
b12 antibody neutralized the J1Hx virus, which has all of the gp41
changes, most potently. Thus, the differential potency of CD4BS
antibodies, which is dictated by the efficiency with which envelope
glycoprotein trimer binding occurs [61], applies in the context of
globally sensitive envelope glycoproteins. In summary, the
neutralization of this panel of viruses depends upon both the
efficiency of antibody binding to the envelope glycoprotein trimer
and a function dictated by the gp41 changes that results in global
virus sensitivity to the bound antibody.
A similar correlation between CD4 independence and sensitiv-
ity to neutralization was observed for the panel of envelope
glycoprotein variants with the V1/V2 variable loops deleted
(Figure S7). Sensitivity of the viruses to both sCD4 and the 2F5
antibody was cooperatively determined by the gp41 changes and
the deletion of the V1/V2 loops. As expected [62], all of the
envelope glycoprotein variants that contain a deletion of the V1/
V2 loops exhibited greater sensitivity to 2G12 neutralization due
to increased binding of this antibody.
We also examined the effect of the H66N and S375W gp120
changes that respectively decrease and increase the spontaneous
sampling of the CD4-bound state by the HIV-1 envelope
glycoproteins [58,59,63,64]. As shown above (Figure S5A and B),
the H66N change decreases the efficiency of CD4-independent
infection; by contrast, the S375W change exerted little specific
impact on CD4 independence (Figure S8A). In accordance with
previous observations [58], the H66N change reduced HIV-1
sensitivity to sCD4-mediated inhibition (Figure S8B). However, the
H66N change did not affect the sensitivity of HIV-1 to CD4BS
antibodies or to the 2F5 antibody (Figure 5 and Figure S8, C–F).
The S375W change increased viral sensitivity to inhibition by sCD4
and the 17b antibody, but did not significantly affect sensitivity to
the b6, b12, F105 or 2F5 antibodies. Therefore, the H66N and
S375W changes specifically affect HIV-1 sensitivity to ligands like
sCD4 and 17b that preferentially recognize the CD4-bound state.
However, in contrast to the gp120 and gp41 changes associated
with CD4 independence, the H66N and S375W changes do not
globally affect the sensitivity of HIV-1 to inhibition.
Inhibitor Binding to the HIV-1 Envelope Glycoprotein
Variants
We examined whether the increased inhibitor sensitivity of
viruses with CD4-independent envelope glycoproteins is a
consequence of increased binding of the inhibitor to the envelope
glycoprotein trimer. Despite significant differences among the
envelope glycoprotein variant viruses in sensitivity to sCD4, 2F5
and 2G12, there was no evident correlation between inhibition
sensitivity and steady-state binding of the inhibitor to the envelope
glycoprotein trimer (Figure 6). Weak trends were observed for the
CD4-induced antibodies 17b and 48d, which likely represent the
effect of increased exposure of the CoR-BS induced by the N197S
change. Accordingly, the N197S change increased the on-rate of
17b binding to the cell surface envelope glycoprotein trimer
(Figure S9A).
We note that variation in inhibitor-induced shedding of gp120
from the envelope glycoprotein trimer did not explain differences
in neutralization sensitivity of viruses with these envelope
glycoprotein variants (Figure S9, B and C).
The above results indicate that the changes in the gp41
ectodomain, in particular the HT and N sequences, significantly
increase HIV-1 sensitivity to neutralization by antibodies that
recognize a variety of different envelope glycoprotein structures
and by a CD4-mimetic compound. In most cases, the increased
neutralization sensitivity cannot be explained by increases in
antibody binding to the envelope glycoprotein trimer. These same
gp41 changes are also responsible for the increased capacity of the
envelope glycoproteins to infect cells in a CD4-independent
manner (i.e., increased CCR5 responsiveness). In summary, both
the gp41 changes and the deletion of the V1/V2 loops are
responsible for the increased propensity of the HIV-1 envelope
glycoproteins to negotiate spontaneously the transition into a
conformation in which the HR1 coiled coil is formed and exposed.
In this state the envelope glycoproteins have increased respon-
siveness to the CCR5 coreceptor. The gp41 changes and V1/V2
loop deletion also induce a state of increased reactivity to the
binding of inhibitory ligands that target a wide range of envelope
glycoprotein epitopes.
Relationship between CD4 Independence and Cold
Inactivation
HIV-1 envelope glycoproteins that more frequently sample the
CD4-bound state are more prone to inactivation by exposure to
cold [63]. We therefore examined the possible linkage between
CD4 independence and cold sensitivity. To measure cold
sensitivity, we incubated virus on ice for different time periods
and then added the virus to CD4
+CCR5
+ cells to measure
infectivity. The J1Hx chimeric construct was highly sensitive to
cold-induced inactivation, with or without the N197S change
(Figure 7A, left panel). The main determinant of cold sensitivity
was the gp41 HT change. The gp41 N change mildly increased
sensitivity to cold (Figure S10A) and also enhanced the cold
sensitivity of the HT variant. By contrast, the N197S change,
which increases coreceptor-binding site exposure and enhances
CD4-independent infection, exerted a slightly negative effect on
cold sensitivity. For the group of N197S-containing envelope
glycoprotein variants with different gp41 ectodomains, cold
of the V1/V2 loops with the gp41 changes. (D, right) Correlation between relative CD4-independent infectivity of V1/V2 loop-deleted envelope
glycoproteins and their relative CD4-independent binding of C34-Ig. The Spearman rank-order correlation coefficient is indicated (*, P,0.05). (E)
Effect of the H66N change (indicated by 66) and the S375W change (indicated by 375) on the relative CD4-independent binding of C34-Ig (30 mg/ml)
to COS-1 cells expressing the indicated cytoplasmic tail-deleted envelope glycoprotein variants at 16uC. The deletion of the gp120 V1/V2 variable
loops is indicated by DV. (F) C34-Ig binding to the envelope glycoproteins of the HIV-1 8x strain. COS-1 cells that transiently express the indicated
envelope glycoproteins were incubated with C34-Ig (40 mg/ml) in the absence or presence of sCD4 (20 mg/ml) at 25uC. The cytoplasmic tail of the
‘‘full-length’’ (FL) 8x envelope glycoprotein is truncated and is composed of 27 amino acid residues (see ref. [29]). To eliminate any potential bias
caused by cytoplasmic tail length, C34-Ig binding was measured to the full-length and truncated (Dct) form of both HIV-1 AD8 and 8x envelope
glycoproteins. The cytoplasmic tail of both Dct envelope glycoproteins contains one amino acid (truncated after Asn 706). Binding of mAb IgG1 b12
(1 mg/ml) was also measured (bottom panel). Values represent means (6 SEM) derived from duplicate samples.
doi:10.1371/journal.ppat.1002101.g003
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(Figure 7A, right panel). This correlation is consistent with a
model in which the same property that is dictated by the gp41
changes and that affects coreceptor reactivity and global inhibitor
sensitivity is also responsible for increased sensitivity of the
envelope glycoproteins to cold-induced inactivation.
Deletion of the V1/V2 loops resulted in a dramatic increase in
cold sensitivity; the half-life on ice of approximately 19 hours for
viruses with the AD8 envelope glycoproteins was reduced to
0.5 hours for the V1/V2-deleted mutant (Figure 7B, left panel).
Combination of the V1/V2 deletion and the gp41 HT change
further increased cold sensitivity. The cold sensitivity and CD4
independence of this panel of V1/V2-deleted envelope glycopro-
teins also exhibited a strong correlation (Figure 7B, right panel).
Changes in gp120 that were previously shown to decrease
(H66N) or increase (S375W) gp120 sampling of the CD4-bound
conformation [58,59,63] increased or decreased, respectively, the
half-lives of the AD8 envelope glycoproteins on ice ([63] and Figure
S10B). Similarly, incubation of the HIV-1 variants with sub-
neutralizing concentrations oftheCD4-mimetic compound JRC-II-
191 resulted in increased cold sensitivity (Figure S10C). Removal of
the cytoplasmic tail did not alter the pattern or absolute level of cold
sensitivity of the envelope glycoprotein panel (Figure S10D).
Increased cold sensitivity was not associated with an increased
propensity to shed gp120 from the envelope glycoprotein trimer.
Incubation of viruses on ice did not result in release of gp120 from
virions, as measured by the amount of residual infectivity in a virus
capture assay (Figure S10E) or by changes in the level of gp120 in
the supernatant (Figure S10F).
In summary, three alterations in the envelope glycoproteins (the
HT and N changes in gp41 and the V1/V2 deletion in gp120)
contributed to the capacity of HIV-1 to infect CD4
2CCR5
+ cells,
but also increased virus susceptibility to neutralizing ligands and to
cold-induced inactivation. We designate this property of increased
sensitivity to coreceptor, inhibitors and cold temperatures
‘‘intrinsic reactivity’’. Intrinsic reactivity describes the propensity
of the HIV-1 envelope glycoproteins to negotiate transitions to
another state upon perturbation by ligand binding or thermal
stimulation. Of note, although HIV-1 envelope glycoprotein
variants that exhibit increased intrinsic reactivity are more cold-
sensitive, the converse is not true; some cold-sensitive envelope
glycoproteins (e.g., S375W) are not globally sensitive to antibody
neutralization and thus cannot be considered intrinsically reactive.
Therefore, additional paths to the cold-sensitive state exist that do
not involve an increase in intrinsic reactivity.
Relationship between Inhibitor Binding and Inhibitor
Efficiency in Envelope Glycoproteins Derived from
Primary HIV-1 Isolates
in vivo propagation of HIV-1, in the absence of immune
selective pressure, is often associated with a generalized increase in
sensitivity to neutralization by antibodies [41,65,66]. Passage of
simian-human immunodeficiency viruses containing the envelope
glycoproteins of these laboratory-adapted HIV-1 strains in
monkeys resulted in reversion of the neutralization-sensitive
viruses to more resistant forms [67,68]. Similarly, in vitro passage
of HIV-1 in the presence of neutralizing antibodies also generated
globally neutralization-resistant viruses [69,70]. Global changes in
sensitivity to antibodies are often induced by a limited number of
changes in envelope glycoprotein sequence [32,39,40]. In several
cases, the changes in neutralization sensitivity could not be
explained solely on the basis of changes in binding affinity of the
Figure 4. Association of CD4 independence and global neutralization sensitivity. (A) Sensitivity of viruses containing the indicated
envelope glycoprotein variants to different inhibitors. The relative infectivity of each envelope glycoprotein variant for CD4
2CCR5
+ cells is shown for
comparison. The relative levels of both CD4 independence and neutralization sensitivity are color coded as indicated. (B–E) Neutralization of viruses
with the indicated envelope glycoproteins by sCD4 and antibodies. Each envelope glycoprotein variant is color coded according to its relative CD4-
independent infectivity. (F) Correlation between the relative CD4-independent infectivity of envelope glycoprotein variants and sensitivity to
neutralization. The Spearman rank-order correlation coefficient is indicated (*, P,0.05).
doi:10.1371/journal.ppat.1002101.g004
Figure 5. Effect of the H66N and S375W changes on neutralization sensitivity. Sensitivity of viruses containing the indicated envelope
glycoprotein variants to the different inhibitors was measured and an IC50 or IC25 value determined. The capacity of each envelope glycoprotein
variant to mediate infection of CD4
2CCR5
+ cells, relative to the ability to mediate infection of CD4
+CCR5
+ cells, is indicated for comparison. The
relative levels of both CD4 independence and sensitivity to neutralization by each inhibitor are color-coded, as in Figure 4A. ND, not determined.
doi:10.1371/journal.ppat.1002101.g005
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hypothesized that, in such cases, alterations in the intrinsic
reactivity of the envelope glycoproteins contribute to the observed
changes in HIV-1 neutralization sensitivity.
The above-described chimeras between the envelope glycopro-
teins of AD8 and HXBc2 strains of HIV-1 were generated
artificially. We sought to determine the potential role of intrinsic
reactivity in the phenotypes of primary viruses cloned directly
from HIV-1-infected individuals. For this purpose, we used a
standardized panel of 16 envelope glycoproteins derived from
diverse primary HIV-1 isolates, which serve as the reference
strains for assessment of vaccine-elicited neutralizing antibodies
[71]. These envelope glycoproteins have been classified on the
basis of sensitivity of viruses containing them to neutralizing
antisera: Tier 1 viruses are more sensitive than Tier 2 viruses to
antibody neutralization [72]. In a recent study, the Tier 1 group of
envelope glycoproteins was subdivided based on mean sensitivity
of the associated viruses to six pools of human plasma into Tier 1A
and Tier 1B classes [73].
To examine the basis for the increased neutralization sensitivity
of Tier 1 HIV-1 isolates, we tested several inhibitors, including
sCD4 and the monoclonal antibodies IgG1 b12, 2G12, and 4E10.
A general trend of increased sensitivity of the Tier 1 viruses
relative to the Tier 2 viruses was observed; 2-tailed T-test P values
were 0.0495, 0.0884, 0.168 and 0.271 for sCD4, 2G12, 4E10 and
IgG1 b12, respectively (Figure S11).
We asked whether the observed differences in susceptibility of
the primary viruses to neutralization by these inhibitors results
from the differential binding of the inhibitors to the envelope
glycoproteins. For this purpose, we measured binding of the
inhibitors to the envelope glycoprotein trimers using a cell-based
ELISA. Binding data were normalized for the level of cell-surface
expression of each envelope glycoprotein, which was determined
by a cell-surface immunoprecipitation assay (see Materials and
Methods). As shown in Figure 8A, significant correlations between
binding to the envelope glycoprotein complexes and virus
neutralization were observed for the monoclonal antibodies
IgG1 b12 and 2G12. By contrast, for both the 4E10 antibody
and sCD4, there was no clear correlation between inhibitor
binding and neutralization potency.
The absence of a binding-inhibition correlation for some of the
inhibitors suggested that an envelope glycoprotein property
influencing susceptibility to the bound inhibitor might be
contributing to the neutralization sensitivity of the virus. To
examine this possibility, we calculated the ratio of neutralization
sensitivity of the virus to the efficiency of ligand binding to the cell-
surface envelope glycoproteins for each of the four inhibitors tested
(Figure S12A–D). This neutralization-to-binding ratio quantita-
tively describes the ‘‘reactivity’’ of the envelope glycoproteins to
the binding of inhibitors. The envelope glycoproteins of the panel
were arranged in rank order of their neutralization-to-binding
ratios, whereby the strain with the highest sensitivity was assigned
the maximal value of 15 and the lowest a value of one. In addition,
for each envelope glycoprotein, the mean of its relative rank order
for the four inhibitors tested was calculated and is designated the
average neutralization-to-binding index (Figure 8B). By averaging
the rank orders rather than using absolute neutralization-to-
binding ratios, we imparted an identical weight to the results
obtained from each of the tested antibodies and thus eliminated
potential bias introduced by any single value.
Viruses containing Tier 1 envelope glycoproteins had signifi-
cantly higher average neutralization-to-binding indices than
viruses containing Tier 2 envelope glycoproteins (Figure 8B).
Two-tailed T-test P values were 0.007 for a comparison of Tier 1A
with Tier 1B and Tier 2 envelope glycoproteins, and 0.018 for the
comparison of Tier 1A and Tier 1B with Tier 2 envelope
glycoproteins. The Tier 1B envelope glycoproteins from the
6535.3 HIV-1 strain, previously categorized as a Tier 2 virus [72],
exhibited only a moderate level of sensitivity to inhibitor binding
relative to the Tier 1A viruses. When a comparison between Tier 1
and Tier 2 viral envelope glycoproteins was made for the
neutralization-to-binding ratios of the individual inhibitors rather
than the averaged index, a statistically significant difference was
found for sCD4 and a trend towards significance for the 4E10
antibody (Figure S12, A–D). These results suggest that envelope
glycoproteins of primary HIV-1 strains differ in their reactivity to
the binding of inhibitors; Tier 1 viruses are generally more
sensitive than Tier 2 viruses to inhibitor binding. Thus, as shown
for the panel of AD8 variants, not only the binding efficiency of
the inhibitor but also the reactivity of the envelope glycoproteins to
the binding event determines the level of HIV-1 susceptibility to
the inhibitor.
We note that envelope glycoprotein cleavage status did not
differ between the Tier 1 and Tier 2 isolates. We performed a cell-
surface immunoprecipitation of the Tier 1/Tier 2 envelope
glycoproteins using the b12, 2G12 and VRC01 antibodies. No
significant differences in the gp120 to gp160 ratios for the cell
surface fraction were observed between envelope glycoproteins of
Figure 6. Relationship between neutralization sensitivity and
inhibitor binding. The binding of inhibitors to the indicated envelope
glycoproteins expressed on the cell surface was measured at 37uC. To
normalize for cell-surface expression, inhibitor binding was calculated
as percent binding of the control 2G12 antibody. Correlations between
inhibitor binding to each envelope glycoprotein variant and the
inhibitor IC50 or IC25 for viruses with the same envelope glycoprotein
were examined. The Spearman rank-order correlation coefficient is
indicated (*, P,0.05).
doi:10.1371/journal.ppat.1002101.g006
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which the HIV-1 envelope glycoproteins are cleaved can influence
the binding of the non-neutralizing CD4BS antibodies, b6 and
b13, compared with that of the neutralizing CD4BS antibody b12
[61]. We therefore measured the binding of the b6, b13 and b12
antibodies to the primary envelope glycoproteins expressed on
COS-1 cells using the cell-based ELISA. No differences were
observed between the two Tiers in absolute levels of b6 or b13
binding or in their binding relative to the b12 antibody (data not
shown). These results are in agreement with those obtained for the
panel of AD8 variants that show no particular trend in the
cleavage status of the intrinsically reactive envelope glycoproteins
that would bias our results.
Cold Sensitivity of Neutralization-Sensitive and -Resistant
Primary HIV-1 Strains
We hypothesized that the increased sensitivity to inhibitor
binding of the Tier 1 envelope glycoproteins is a consequence of
an increased level of intrinsic reactivity. As our previous results
indicated that intrinsically reactive envelope glycoproteins are
cold-sensitive, we examined the cold sensitivity of the primary
HIV-1 envelope glycoprotein panel. As shown in Figure 9A, all of
the viruses pseudotyped with the Tier 1 envelope glycoproteins
were highly sensitive to cold inactivation. By contrast, the Tier 2
viruses were more cold-resistant (two-sided P-value=0.011,
Wilcoxon-Mann-Whitney test). Tier 2 viruses exhibited significant
variability in cold sensitivity; IT25 values ranged from 2 hours to
more than 100 hours. We also examined the envelope glycopro-
teins derived from a panel of transmitted/founder HIV-1 isolates,
which generally exhibit phenotypes characteristic of Tier 2 viruses
[73]. Similar to the panel of Tier 2 envelope glycoproteins, the
transmitted virus envelope glycoproteins also exhibited a wide
range of sensitivities to cold inactivation.
Although Tier 1 envelope glycoproteins were highly cold-
sensitive relative to the Tier 2 panel, there was only a weak trend
between cold sensitivity and the level of global reactivity to
inhibitor binding, as measured by the neutralization-to-binding
index for the 4 inhibitors (Figure S13A). Therefore, although cold
sensitivity can serve as a highly sensitive measure of a global
neutralization-sensitive state, it is not specific for this state. This
conclusion is consistent with the results obtained with the S375W
and H66N changes in gp120, which affect cold sensitivity but not
global neutralization sensitivity. Both gp120 changes, however,
demonstrated specific effects on sensitivity to sCD4 (Figure 5). We
therefore examined the panel of primary HIV-1 envelope
glycoproteins for a relationship between sensitivity to cold and
Figure 7. Relationship between CD4 Independence and cold sensitivity. (A,B) In the left panels, viruses containing the indicated envelope
glycoproteins were incubated on ice for different times and then added to CD4
+CCR5
+ Cf2Th cells. The data represent mean (6 SEM) levels of
infection measured for each time point as a percent of the level of infection measured for viruses directly thawed from frozen stocks. Envelope
glycoproteins are color coded according to relative CD4-independent infectivity. In the right panels, correlations are shown between CD4-
independence (expressed as percent of the maximal infection of CD4
2CCR5
+ cells measured for the tested panel of variants) and cold resistance. For
the correlations, cold resistance is expressed as half-life for the panel of envelope glycoprotein variants that contain the N197S change (A), or as the
residual infectivity after a 7-hr incubation on ice (B). The Spearman rank-order correlation coefficient is indicated (*, P,0.05).
doi:10.1371/journal.ppat.1002101.g007
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Binding of the indicated inhibitors to COS-1 cells expressing envelope glycoproteins from primary HIV-1 isolates was measured at 37uC using the cell-
based ELISA; the antibodies IgG1 b12, 2G12 and 4E10 were added at a concentration of 1 mg/ml and CD4-Ig was added at 2 mg/ml. Binding was
normalized for cell-surface expression measured by cell-surface immunoprecipitation from
35S-labeled cells (see Materials and Methods section). The
relationship between neutralization sensitivity of viruses containing the envelope glycoproteins (given by the 1/IC50 value) and the normalized
binding efficiency is shown. The envelope glycoproteins are colored according to neutralization sensitivity (Tier 1A, black; Tier 1B, grey; and Tier2 ,
empty symbols). The Spearman rank-order correlation coefficient is indicated (*, P,0.05). (B) A generalized measure of envelope glycoprotein
sensitivity to the binding of inhibitors. For each envelope glycoprotein, the ratio of the neutralization sensitivity and binding efficiency of each of the
inhibitors, as described in panel (A), was calculated (See Materials and Methods). For each inhibitor tested, the envelope glycoproteins were rank
ordered according to their neutralization-to-binding ratios. Shown is the mean (6 SEM) rank order of neutralization-to-binding for each of the
envelope glycoproteins averaged for the four inhibitors. Color coding is the same as that in panel (A).
doi:10.1371/journal.ppat.1002101.g008
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inhibiting ligands examined, only the sCD4 neutralization-to-
binding ratio correlated with sensitivity to cold. This correlation
was supported by examining a larger panel of envelope
glycoproteins from 26 primary HIV-1 isolates, including Tier 1,
Tier 2 and transmitted/founder isolates (see list in Materials and
Figure 9. Relationship between cold sensitivity and inhibitor sensitivity of primary HIV-1 envelope glycoproteins. (A) Sensitivity to
cold-induced inactivation of viruses containing envelope glycoproteins derived from a standardized panel of primary HIV-1 isolates, including
transmitted/founder HIV-1. Data represent the mean incubation time on ice required for a 25% decrease from initial infectivity (IT25) in an experiment
performed with three replicate samples. Color coding is the same as that in Figure 8. (B) Correlation between the cold sensitivity of viruses and their
reactivity to the binding of sCD4. The neutralization-to-binding ratio is defined as the reciprocal of the IC50 value of the virus containing the envelope
glycoproteins divided by the efficiency of sCD4 binding to the envelope glycoprotein trimer (normalized for the level of cell-surface expression). The
26 envelope glycoproteins included in the cohort are listed in the Materials and Methods section. *, Two-tailed T-Test P value 0.000112. (C)
Correlation between sCD4 sensitivity and the product of CD4-Ig binding to cell-surface envelope glycoproteins and cold sensitivity. The sCD4
sensitivity of viruses with the envelope glycoproteins from the primary HIV-1 cohort was plotted versus the product of cold sensitivity and CD4-Ig
binding to cell-surface envelope glycoproteins (normalized for cell-surface expression). *, Two-tailed T-Test value P value 0.00006.
doi:10.1371/journal.ppat.1002101.g009
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neutralization could be predicted by two factors: CD4 binding
to the cell-surface envelope glycoproteins and cold sensitivity
(Figure 9C). Interestingly, the relationship between the neutrali-
zation-to-binding ratio and cold sensitivity was more apparent for
sCD4 and 4E10 than for IgG1 b12 and 2G12 (Figure S13B–E).
This is consistent with envelope glycoprotein intrinsic reactivity
playing a role in sCD4, and perhaps 4E10, neutralization. For
such inhibitors, which are dependent upon both binding and
intrinsic reactivity for inhibition, a lower level of correlation
between binding and inhibition is expected. By contrast, for
antibodies that are less dependent upon envelope glycoprotein
reactivity for inhibition (such as IgG1 b12 and 2G12), binding
efficiency to the envelope glycoprotein trimer is the dominant
determinant and correlates well with neutralization sensitivity.
In summary, the neutralization-to-binding index serves as both
a sensitive and specific indicator of the level of global sensitivity
(reactivity) to inhibitors. By contrast, cold sensitivity serves as a
sensitive measure of intrinsic envelope glycoprotein reactivity but
has low specificity. The cold-sensitive state, regardless of the level
of global neutralization sensitivity, is generally associated with an
increased envelope glycoprotein reactivity to sCD4 binding.
Discussion
Persistent viruses like the primate immunodeficiency viruses
must avoid envelope glycoprotein-directed neutralizing antibodies.
The use of two receptors for virus entry allows sequestration of the
coreceptor-responsive (but also inhibitor-reactive) state from the
humoral immune system of the host [74,75]. The relatively
neutralization-resistant unliganded viral envelope glycoprotein
spike is activated by engagement of the primary receptor, CD4,
and is thus primed for subsequent events on the entry pathway. At
the virus-cell interface, the CD4-bound state is relatively stable
and protected from most neutralizing antibodies by steric factors
[75]; by contrast, the sCD4-bound state on free HIV-1 virions is
labile and highly sensitive to antibody neutralization [33,34,47].
Viruses adapting to host compartments with different levels of
target cell CD4 and neutralizing antibodies must balance envelope
glycoprotein requirements for entry, antibody resistance and
stability. Here, by studying a panel of HIV-1 envelope
glycoproteins differing incrementally in CD4 dependence, we
define the entry functions provided by CD4 binding, identify a
novel property of the HIV-1 envelope glycoproteins and clarify
how this property influences virus entry and sensitivity to
inhibitors and environmental factors.
The phenotypic effects of the envelope glycoprotein changes
and the correlations among these phenotypes suggest a model for
the contributions of CD4 binding to HIV-1 entry (Figure 10). CD4
binding to gp120 facilitates two events, both of which contribute to
the formation/exposure of the gp41 HR1 coiled coil and virus
entry. One event is the formation and exposure of the gp120
binding site for CCR5 and/or CXCR4. CD4-independent
envelope glycoproteins can spontaneously expose the CoR-BS, a
state that is associated with increased recognition by antibodies
directed against CD4-induced epitopes. A strong correlation exists
between CD4 independence and exposure of these epitopes.
Changes in the gp41 ectodomain contributed to CD4
independence, global neutralization sensitivity, and cold suscep-
tibility, yet exerted little or no effect on CoR-BS exposure or
antibody binding to the envelope glycoprotein trimer. These
observations suggest the existence of a property of the HIV-1
envelope glycoproteins that we designate ‘‘intrinsic reactivity.’’
Figure 10. Early events in HIV-1 entry. The relationship among the early events in HIV-1 entry that typically are triggered by CD4 binding is
depicted. Increased intrinsic reactivity and exposure of the CoR-BS cooperatively contribute to formation/exposure of the gp41 HR1 coiled coil. The
points at which HIV-1 envelope glycoprotein changes act in either a positive (green) or negative (red) fashion are noted.
doi:10.1371/journal.ppat.1002101.g010
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glycoproteins to undergo transitions from their native high-energy
state to a lower-energy state upon stimulation. In the case of CD4-
independent infection, enhanced intrinsic reactivity increases the
probability that the unliganded HIV-1 envelope glycoproteins will
make the transition to the pre-hairpin intermediate without the
assistance of CD4. This is reflected in the positive effect of the
gp41 changes on the spontaneous formation/exposure of the HR1
coiled coil. Enhanced intrinsic reactivity is also manifest as a global
reactivity of HIV-1 to bound ligands (antibodies, sCD4 and small
molecules) and to exposure to the cold; in these cases, the HIV-1
envelope glycoproteins apparently make transitions to non-
functional states. Cold sensitivity indicates that intrinsic reactivity
is an intrinsic property of the envelope glycoproteins and is not
dependent on the presence of a ligand. The observed range of
susceptibility of envelope glycoproteins to cold inactivation and the
quantitative correlation of those values with CD4-independence
indicate that intrinsic reactivity may assume multiple values (i.e., is
not a binary variable).
Exposure of the CoR-BS and increases in intrinsic reactivity
independently promoted the formation/exposure of the gp41
HR1 coiled coil. The ability of the HIV-1 envelope glycoprotein
variants to bind the gp41 HR2 peptide (C34-Ig) in a spontaneous
manner was tightly correlated with the ability to mediate CD4-
independent infection. C34-Ig binding indicates that, in CD4-
independent HIV-1 envelope glycoproteins, the HR1 coiled coil is
either already formed or can readily be formed in the presence of
soluble HR2 peptides. Exposure of the HR1 coiled coil
presumably sets the stage for coreceptor binding to trigger
subsequent events in the entry process, such as formation of the
six-helix bundle.
Conformational transitions from the unliganded state of the
HIV-1 envelope glycoprotein trimer presumably involve move-
ment from a local energy well over an activation barrier and down
a steep energy gradient [1,3,16,17]. We suggest that increases in
intrinsic reactivity may decrease this activation barrier by
loosening the quaternary constraints that preserve the unliganded
state. This perspective helps to explain the particular sensitivity of
intrinsically reactive HIV-1 envelope glycoproteins to cold and to
ligand binding. Cold denaturation of proteins often involves the
formation of ice-like water structures surrounding hydrophobic
interfaces in oligomeric protein complexes [76]. Any decrease in
the quaternary associations that maintain the unliganded state
may expose envelope glycoprotein elements that are otherwise
buried in the trimer, rendering them available for interaction with
water during cold inactivation. The binding of some ligands
induces significant conformational changes in the HIV-1 envelope
glycoproteins [3,60] and may also predispose the HIV-1 envelope
glycoproteins to move to lower-energy states.
Soluble CD4 binding induces major conformational changes in
the envelope glycoprotein spike [2], driving the unliganded HIV-1
envelope glycoproteins into an unstable activated intermediate.
The short-lived intermediate is characterized by increased
exposure of the HR1 coiled coil and the capacity to infect
CD42 cells [47]. Treatment with sCD4 or CD4-mimetic
compounds also sensitizes the HIV-1 envelope glycoproteins to
cold inactivation [58]. These observations hint that an increase in
intrinsic reactivity may accompany CD4 binding and thus may
represent a step in HIV-1 infection of CD4
+ cells; from this
perspective, an increase in intrinsic reactivity is not merely a
means by which CD4-independent viruses bypass the requirement
for CD4. Some V1/V2 loop-deleted envelope glycoprotein
variants studied here exhibited spontaneous formation/exposure
of the HR1 coiled coil that approached the level induced by sCD4
treatment; the functional viability of these variants suggests that
the intermediate states sampled must exhibit at least modest
stability. Of interest, the HXBc2 gp41 sequences associated with
CD4 independence increased the longevity of HR1 coiled coil
exposure following sCD4 treatment. These observations suggest
that: 1) some CD4-independent viruses may have acquired
changes that increase the stability of the envelope glycoproteins
when assuming conformations that are near the CD4-bound state;
and 2) the instability of the sCD4-activated envelope glycoproteins
results from a process that is distinct from the formation/exposure
of the HR1 coiled coil and is unnecessary for infection of
CD4
2CCR5
+ cells. Therefore, although activation by CD4 during
the entry process and inactivating events resulting from exposure
to sCD4 or cold involve HIV-1 envelope glycoprotein transitions
down an energy gradient, the resulting states differ in functionality.
This separation explains how the sCD4-activated state of the SIV
envelope glycoproteins can persist for several hours at 37uC
[4,5,77] and how the envelope glycoproteins of some CD4-
independent SIV strains exist constitutively in a conformation
resembling the CD4-bound state [78].
The property of intrinsic reactivity explains the long-standing
observation that in vivo or tissue-culture adaptation of HIV-1 to
replicate in cells with low levels of CD4 results in increased
sensitivity to neutralization by sCD4 and antibodies. At least two
factors determine the outcome of the exposure of HIV-1 to an
inhibitor directed against the envelope glycoproteins: a) the ability
of the inhibitor to bind the functional envelope glycoprotein
trimer; and b) the intrinsic reactivity of the viral envelope
glycoproteins. Antibody binding to the envelope spike is a
prerequisite for neutralization and, for HIV-1 variants with low
intrinsic reactivity, represents the dominant determinant of
neutralization potency. Epitope exposure contributes to the
sensitivity of CD4-independent envelope glycoproteins to neutral-
ization by the antibodies directed against CD4-induced gp120
epitopes. These were the only antibodies examined for which
antibody binding to the envelope glycoprotein trimer exhibited
any correlation with neutralization of the HIV-1 AD8 variants.
For the other antibodies and inhibitors studied with this virus
panel, altered intrinsic reactivity of the envelope glycoprotein is
required to explain the observed differences in neutralization
sensitivity. It is noteworthy that the CD4-BS antibody b12, which
binds the HIV-1 envelope glycoprotein trimer more efficiently
than the closely related b13 antibody [61], uniformly neutralized
our panel of CD4-independent viruses better than b13. Thus, the
envelope glycoprotein structures that influence the differential
binding of these antibodies to the trimer [61] must be preserved
over a range of intrinsic reactivities.
Our results suggest that intrinsic reactivity also influences the
sensitivity of some primary HIV-1 strains to neutralization by
antibodies or sCD4. By measuring the neutralization-to-binding
ratios for individual antibodies and generating an averaged index,
we found that the envelope glycoproteins of Tier 1 primary HIV-1
exhibit increased reactivity to the bound ligands, relative to Tier 2
viruses. The globally neutralization-sensitive Tier 1 envelope
glycoproteins did not bind inhibitory ligands more efficiently than
the globally-resistant (Tier 2-like) envelope glycoproteins. Negligi-
ble infection of CD4
2CCR5
+ cells was measured in the panel of
primary virus isolates (data not shown). Furthermore, no
significant differences in exposure of the coreceptor binding site
was observed between Tier 1 and Tier 2 envelope glycoproteins
(data not shown). Therefore, the increased sensitivity of Tier 1
viruses is not associated with an increased propensity to occupy a
CD4-bound state nor can it be attributed to global or localized
differences in antigenicity. Rather, an increased level of envelope
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phenotype.
Although neutralization-resistant Tier 2 HIV-1 are more
common in vivo, Tier 1 viruses emerge and may predominate in
compartments, like the central nervous system, with potential
target cells expressing low levels of CD4. HIV-1 with low CD4
requirements for entry are probably counterselected by the
humoral immune response. Indeed, passage in monkeys of a
simian-human immunodeficiency virus bearing the envelope
glycoproteins of the Tier 1 HIV-1 HxBc2 resulted in a
neutralization-resistant virus; of note, changes in the gp41 residues
626 and 674, which were identified in our study as determinants of
intrinsic reactivity, occurred during the passage and were shown to
contribute to neutralization resistance [67].
The magnitude of the effect of changes in intrinsic reactivity on
neutralization sensitivity depended upon the inhibitory ligand.
This ligand dependency was similarly observed in both the panel
of AD8 variants and in the panel of primary HIV-1 isolates,
including Tier 1, Tier 2 and transmitted/founder viruses. Thus,
antibodies (such as 2G12 and IgG1 b12) that demonstrated low
dependence on intrinsic reactivity for inhibition in the panel of
AD8 variants also demonstrated a lower dependence on intrinsic
reactivity for inhibition within the cohort of primary isolates;
neutralization of the primary viruses by these antibodies correlated
well with envelope glycoprotein trimer binding. Future studies will
investigate the ligand-specific properties that influence the impact
of intrinsic reactivity on the susceptibility of HIV-1 to neutrali-
zation.
Future studies will also be directed towards identifying better
structural and/or phenotypic markers of HIV-1 envelope
glycoprotein intrinsic reactivity. Although intrinsically reactive
envelope glycoproteins were found to be sensitive to cold exposure
and to inhibition by sCD4, neither of these properties were specific
indicators of intrinsic reactivity. The S375W gp120 mutant and
some Tier 2 HIV-1 were found to be cold-sensitive but not
globally neutralization-sensitive, suggesting that pathways to cold
sensitivity exist that do not involve increases in intrinsic reactivity
(see Figure 10). It is noteworthy that the sensitivity of a range of
Tier 1, Tier 2 and transmitted/founder HIV-1 to sCD4 inhibition
was predicted only by taking into account both sCD4 binding to
the envelope glycoprotein trimer and cold sensitivity. The utility of
the latter parameter in strengthening the correlation between
sCD4 binding and inhibition supports the relatedness of the
envelope glycoprotein changes that predispose to HIV-1 inactiva-
tion by cold or sCD4 engagement. Understanding these changes
will be helpful in potentiating the HIV-1-inactivating mechanisms
of CD4-mimetic small molecules.
The concept of intrinsic envelope glycoprotein reactivity will
assist our understanding of primate immunodeficiency virus
adaptation to host body compartments, immune responses and
antiviral agents.
Materials and Methods
Reagents and Antibodies
The IgG1 b12 antibody, which recognizes the CD4-binding site
of gp120 [79,80], and the PG16 antibody, which recognizes a
trimer-sensitive epitope dependent on the gp120 V1/V2 and V3
variable loops [50], were kind gifts from Dennis Burton. The F105
antibody, which also recognizes the gp120 CD4-binding site [81],
was kindly provided by Marshall Posner [82]. James Robinson
kindly provided the following antibodies: 17b and 48d, which
recognize gp120 epitopes that are induced by CD4 binding [49],
and the anti-gp41 antibodies 7B2 and 2.2B [83]. The 2G12
antibody, which targets a carbohydrate-dependent gp120 epitope
[48], and the 2F5 antibody, which recognizes the membrane-
proximal external region (MPER) of gp41 [84], were provided by
Hermann Katinger. The CD4-binding site-directed antibodies b6
and b13 were provided by Dennis Burton and Peter Kwong
[61,85]. The D49 antibody recognizes the gp41 cluster I
immunodominant epitope [86] and was obtained from the
International AIDS Vaccine Initiative (IAVI) Neutralizing Anti-
body Consortium.
The C34 peptide is composed of the HR2 region of the HXBc2
gp41 glycoprotein [amino acid residues 628–661, numbered
according to current convention [87] and was custom synthesized
by American Peptide Co. The C34-Ig fusion protein consists of the
Fc region of human IgG1 linked to two copies of the C34 peptide.
C34-Ig was produced and purified as previously described [53].
The CD4-Ig fusion protein consists of the first two N-terminal
domains of the CD4 molecule and the Fc region of human IgG1.
Purification was carried out as described for the C34-Ig molecule.
Four-domain sCD4 was purified from the culture medium of a
293F producer cell line, as previously described [88]. Compound
JRC-II-191 is a small-molecule CD4-mimetic inhibitor of HIV-1
[89].
Envelope Glycoprotein Constructs
The AD8 clone of HIV-1 (accession number AF004394) is a
derivative of the macrophage-tropic ADA strain (env accession
number M60472). AD8 and ADA envelope glycoproteins were
expressed from the pSVIIIenv vector [90]. The vectors were
constructed by replacing the KpnI(6347)-BamHI(8475) fragment of
the HXBc2 env sequence (accession member K03455) of the
original pSVIIIenv plasmid with the corresponding sequences
from AD8. Chimeras between AD8 and HXBc2 strains were
generated by using the Ale I, Mwo I and Ssp I restriction sites
located in the AD8 env genes at nucleotide positions 8044, 8178
and 8276, respectively (numbered according to current convention
[87]).
Constructs that contain a deletion of the gp120 V1/V2 variable
loops (amino acid residues 128 to 194 deleted) were generated by
the overlap PCR method [91] and contain a Gly-Ala-Gly linker in
place of the V1/V2 loops [92]. Unless otherwise specified, all
envelope glycoproteins with a gp41 cytoplasmic domain deletion
contain a 5-amino acid cytoplasmic tail, truncated after Gln 710.
The DKS construct, which contains an HIV-1 HXBc2 env gene
with a large deletion, was used as negative control. Unless
indicated otherwise, all envelope glycoproteins described have a
complete gp41 cytoplasmic tail.
For studies of HIV-1 sensitivity to cold inactivation, we examined
a panel of 16 CCR5-tropic HIV-1 envelope glycoproteins that serve
as standards for the evaluation of neutralizing antibody responses to
administered vaccines [71,72,73,93]. Tier 1A envelope glycopro-
teinsincluded:cladeA/GDJ263.8;clade B SF162.LS, BAL.26;and
clade C MW965.2612. Tier 1B envelope glycoproteins included
clade B 6535.3. Tier 2 envelope glycoproteins included clade B
QHO692.42, SC422661.8, PVO.4, AC10.029, RHPA4259.7,
TRO.11, THRO4156.18, REJO4541.67, TRJO4551.58, WITO-
4160.33 and CAAN5342.A2, as well as the envelope glycopro-
teins derived from transmitted/founder subtype B clones: WEAU-
d15.410.787, 1006-11.C3.1601, 1054-07.TC4.1499, 1056-10.TA11.
1826, 1012-11.TC21.3257, 6240.08.TA5.4622, 6244.13.B5.4576,
62357.14.D3.4589, 9021.12.B2.4571, 700010040.C9.4520, PRB-
926-04.A9.4237, and SC05.8C11.2344. T h ee n v e l o p eg l y c o p r o t e i n s
of isolates Bx08.16 (clade B) and 271-11 (clade A/G) were included in
studies of sCD4 binding due to their high sensitivity to this reagent.
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Binding of Soluble gp120 to Cells that Express CCR5
Human 293T cells were seeded in 6-well plates (1610
6 cells/
well) and transfected the next day with plasmids that express the
full-length envelope glycoproteins and Tat (0.6 and 0.06 mg/well,
respectively) using Effectene transfection reagent (Qiagen). On the
following day, culture medium was removed and 2 ml of labeling
medium (10% heat-inactivated, dialyzed fetal bovine serum [FBS];
10 mg/ml penicillin-streptomycin solution; 50 mCi/ml
35S-Express
protein labeling mix [Perkin Elmer]; and 2 mM L-glutamine in
Dulbecco’s modified Eagle medium [DMEM]) was added to the
transfected cells. Cells were incubated at 37uC for another day
before the medium was harvested and cleared of cells and debris
by centrifugation (1,0006g for 5 minutes at room temperature)
followed by filtration (0.45-mm pore size filter).
For initial quantitation of gp120 shed into the supernatants,
serial dilutions of the samples were used for immunoprecipitation
by 2.5 ml of pooled serum from HIV-1-infected individuals and
Protein A-Sepharose beads in a total volume of 500 ml. After
incubation for 2 hours at 4uC, the beads were washed once with
DMEM supplemented with 10% FBS (DMEM/10% FBS), three
times with NP40 buffer and once with Tris-NaCl buffer (0.15 M
NaCl, 10 mM Tris, pH 7.5). Beads were then boiled in sample
buffer for 10 minutes. Precipitated proteins were separated by
sodium dodecyl sulfate/polyacrylamide gel electrophoresis (SDS-
PAGE) and quantified by densitometry.
For CCR5 binding measurements, input gp120 concentrations
were equalized according to the above quantitation by dilution with
DMEM. To one set of samples, sCD4 was added to a final
concentration of 200 nM; the other set of samples was left
untreated. All samples were incubated at 37uC for 1 hour and
then added to 3610
6 Cf2Th cells that stably express human CCR5.
The mixtures of supernatant and cells were incubated at 37uC for
2 hours. Cells were then washed three times with DMEM/10%
FBS and lysed with NP40 buffer for 30 minutes at 4uC, with gentle
agitation. Lysates were cleared by centrifugation at 14,0006g for
30 min at 4uC. CCR5-bound gp120 was precipitated by pooled
serum from HIV-1-infected individuals, as described above, and
analyzed by SDS-PAGE and densitometry.
Preparation of Recombinant Luciferase-Expressing
Viruses
Single-round, recombinant HIV-1 viruses that express the
luciferase gene were generated by transfection of 293T cells using
Effectene transfection reagent. Briefly, cells were seeded in 6-well
plate wells (approximately 1.5610
6 cells per well) and transfected
the next day with 0.2 mg of the HIV-1 packaging construct
pCMVDP1DenvpA, 0.6 mg of the firefly luciferase-expressing
construct pHIvec2.luc and 0.2 mg of the plasmid expressing the
HIV-1 Rev protein and the envelope glycoproteins, as previously
described [47]. On the next day, transfection medium was
changed to culture medium (DMEM/10% FBS). Virus-containing
supernatants were collected on the following day, cleared of cell
debris by low-speed centrifugation and filtered through 0.45-mm
filters. Virus particle production was quantified by measuring
reverse transcriptase (RT) activity in virus preparations, as
previously described [94].
Infection by Single-Round Luciferase-Expressing Viruses
Target cells were seeded approximately 16 hours before
infection at a density of 8610
3 cells/well in 96-well luminome-
ter-compatible tissue culture plates (PerkinElmer). For infectivity
assays, virus input was normalized for RT unit content and added
to the cells in a final volume of 150 ml per well. For neutralization
assays, virus was incubated in the presence of the inhibitor for one
hr at 37uC. All infections were carried out by incubation of virus
with cells for two days at 37uC. For neutralization assays, viruses
were incubated with the inhibitor for one hr at 37uC and then
added to CD4
+CCR5
+ Cf2Th cells. Medium was then removed
and cells were lysed with 35 ml of passive lysis buffer (Promega).
Cultures were then subjected to three freeze-thaw cycles. To
measure luciferase activity, 100 ml of luciferin buffer (15 mM
MgSO4, 15 mM KPO4 [pH 7.8], 1 mM ATP, and 1 mM
dithiothreitol) and 50 ml of 1 mM D-luciferin potassium salt (BD
Pharmingen) were added to each well. Luminescence was
recorded using a Berthold LB 960 microplate luminometer.
Virus Sensitivity to Cold Inactivation
Recombinant viruses were generated as described above. Each
preparation was then diluted and aliquoted, one sample for each
prospective time point. All samples were then snap-frozen on dry
ice/ethanol for 15 minutes and stored at 280uC. This method of
freezing significantly reduced virus inactivation during freezing/
thawing. At different time points, the various samples were thawed
by incubation in a 37uC water bath for 2 minutes and then placed
on ice. After incubation on ice for different lengths of time, virus
samples were incubated in a 37uC water bath for 2 minutes and
then added to CD4
+CCR5
+ Cf2Th cells. Two days later, cells
were lysed and assayed for luciferase activity, as described above.
Virus Capture Assay
To measure cold-induced changes in the capacity of virus
particles to bind the 2G12 antibody, we used a virus capture assay
[83]. Viruses that express the luciferase gene and contain both
AD8 mutant envelope glycoproteins and the Vesicular Stomatitis
Virus G glycoprotein (VSV-G) were generated as described above,
with the exception that 0.2 mg of a VSV-G expressing plasmid was
added to the transfection mix. The monoclonal antibody 2G12
was used to coat protein-binding 96-well plates (Costar) by
incubation at 1 mg/ml in PBS for three hours at room
temperature. Wells were then washed 3 times with PBS and
blocked for two hours with 3% BSA. Virus preparations, which
were previously incubated on ice for different time periods were
then added to the wells and incubated for three hours at room
temperature. All wells were subsequently washed three times with
DMEM/10% FBS and then overlaid with CD4
2CCR5
2 Cf2Th
cells (20,000 cells/well). Cells were incubated overnight at 37uC
and then split into luminometer-compatible IsoPlate-96 tissue
culture plates (PerkinElmer). On the following day, cells were lysed
and luciferase activity measured.
Measurement of Cold-Induced Shedding of gp120 from
Virions
Virus preparations were harvested as described above and
centrifuged at 100,0006g for 1 hour at 16uC in a SW-28 rotor
(Beckman) over a cushion of 30% sucrose in PBS. Pelleted virions
were then resuspended in PBS supplemented with 1% BSA
(pH 7.33), aliquoted (100 ml for each time point) and snap-frozen
in dry ice immersed in ethanol. A sample of each variant was
analyzed by SDS-PAGE and Western blotting to determine the
level of envelope glycoprotein incorporation into virions. All other
samples were thawed separately and placed on ice for various
periods of time. As a control, one sample for each envelope
glycoprotein variant was not incubated on ice, but kept frozen.
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for 3 hours; the supernatant was then removed. Both pellet and
supernatant were separated by SDS-PAGE. Proteins were
Western blotted and probed with serum derived from HIV-1-
infected individuals.
Cell-Based Enzyme-Linked Immunosorbent Assay (ELISA)
The binding of antibodies to HIV-1 envelope glycoprotein trimers
expressed on cells was measured using a cell-based ELISA system, as
previously described [47]. Briefly, COS-1 cells were seeded in 96-well
plates (1.8610
4 cells/well) and transfected the next day with 0.1 mgo f
aplasmidexpressingtheenvelopeglycoproteinsand0.01 mgo faT a t -
expressing plasmid per well using Effectene transfection reagent.
Three days later, cells were washed twice with blocking buffer
(35 mg/mlBSA, 10 mg/mlnon-fat dry milk, 1.8 mM CaCl2,1m M
MgCl2, 25 mMTris, pH 7.5 and 140 mM NaCl)andincubatedwith
the indicated primary antibody for 45 minutes. Cells were then
washed four times with blocking buffer and four times with washing
buffer (140 mM NaCl, 1.8 mM CaCl2, 1 mM MgCl2 and 20 mM
Tris, pH 7.5). A horseradish peroxidase-conjugated antibody specific
for the Fc region of human IgG was then incubated with the samples
for 45 minutes at room temperature. Cells were washed 5 times with
blocking buffer and 5 times with washing buffer. HRP enzyme
activity was determined after the addition of 33 mlp e rw e l lo fa1 : 1
mix of Western Lightning oxidizing and luminol reagents (Perkin
Elmer Life Sciences) supplemented with 150 mM NaCl. Light
emission was measured with a Mithras LB 940 luminometer
(Berthold Technologies).
Measurement of Cell Surface Expression Levels of
Envelope Glycoproteins by Immunoprecipitation
COS-1 cells were seeded in 6-well plates and transfected the
next day with 0.8 mg of plasmid expressing the envelope
glycoproteins and 0.08 mg of Tat-expressing plasmid. Thirty hours
after transfection, cells were washed once with cysteine- and
methionine-free DMEM. Then 2 ml of labeling medium contain-
ing
35S-Express protein labeling mix was added (as described for
the CCR5-binding assay). Sixteen hours later, cells were detached
from the plate using PBS supplemented with 7.5 mM EDTA,
washed twice with wash buffer (30 mg/ml BSA in PBS, pH 7.3)
and then incubated at 4uC for one hour with an antibody mix
containing 2.25 mg/ml of each of the antibodies 2G12, VRC01,
412d and CD4-Ig in wash buffer. Cells were subsequently washed
three times with wash buffer and once with PBS and lysed with
NP-40 buffer for 30 minutes at 4uC with gentle agitation. Lysates
were cleared by centrifugation at 14,0006g for 30 min at 4uC.
Antibody-bound gp120 was precipitated using Protein A-Sephar-
ose beads. The protein content in the lysates was measured with
the Bradford assay to adjust for input and samples were
subsequently analyzed by SDS-PAGE and densitometry. Cell-
surface expression levels were defined as the gp120 band intensity
subtracted from background signal (mock-transfected cells).
Steady-state binding of each inhibitor to the cell surface was
measured by cell-based ELISA at 37uC. Inhibitor binding
efficiency is defined as the level of inhibitor binding divided by
the relative level of cell-surface expression. Binding values
(absolute and normalized) that were lower than 1% of the
maximal value measured were excluded from the analysis.
Neutralization-to-Binding Ratios and Average
Neutralization-to-Binding Index
The neutralization-to-binding ratio for a given inhibitor was
calculated by dividing the neutralization sensitivity of viruses
containing the envelope glycoproteins (defined as the reciprocal of
the IC50 value) by the normalized binding of the inhibitor to the
cell-surface envelope glycoproteins, determined as described
above.
The average neutralization-to-binding index was calculated as
follows. Based on the neutralization-to-binding ratio, the envelope
glycoproteins were arranged in rank order and assigned a rank
order value, so that the envelope glycoprotein strain with the
highest ratio was assigned a value of 15 and that with the lowest
ratio was assigned a value of 1. For some of the tests, specific
envelope glycoproteins were eliminated from consideration due to
low binding values (,%1 of the maximal value measured in that
group). For groups containing less than 15 envelope glycoproteins,
the relative rank order values assigned were adjusted to scale of 1
to 15. The assigned rank order values for multiple inhibitors were
averaged to obtain the average neutralization-to-binding index.
Statistical Analyses
To examine the degree of correlation between the different
envelope glycoprotein phenotypes, we calculated the Spearman
rank-order correlation coefficient (rs). This test is well-suited to our
purpose, as it makes no assumptions about the distribution of the
measured variables. Furthermore, a single outlier data point does
not unduly influence the assessment of correlation. Spearman
rank-order correlation coefficients range between values of 21
and +1, with values of +1 indicating that both variables increase
together and value of 21 indicating that one variable increases as
the other variable decreases. An rs value close to zero represents
the absence of a relationship between the ranks. A two-tailed P
value of less than 0.05 was considered significant. To all
correlation diagrams, a regression line was added for demonstra-
tive purposes.
The envelope glycoprotein variants included in each analysis
were:
1. For relative CD4-independent infectivity versus relative
antibody binding (Figure 2C): AD8, AD8(197), J1Hx,
J1Hx(197), J2Hx(197), J3Hx(197), J3Hx(197,HT),
J3Hx(197,N) and J3Hx(197,HT,N);
2. For relative CD4-independent infectivity versus relative C34-Ig
binding (Figure 3C), for relative CD4-independent infectivity
versus inhibitor sensitivity (Figure 4F), and for inhibitor binding
versus inhibitor sensitivity (Figure 6): AD8, AD8(197), J1Hx,
J1Hx(197), J3Hx(197), J3Hx(197,HT), J3Hx(197,N) and
J3Hx(197,HT,N);
3. For relative CD4-independent infectivity versus relative C34-Ig
binding for the panel of envelope glycoprotein variants in
which deletion of the V1/V2 loops was combined with the
gp41 changes (Figure 3D) and for CD4-independent infectivity
versus cold sensitivity (Figure 7B): AD8, AD8(DV), J1Hx,
J1Hx(DV), J2Hx(DV), J3Hx(DV), J3Hx(DV,HT), J1Hx(DV,N)
and J1Hx(DV,HT,N);
4. For relative CD4-independent infectivity versus cold sensitivity
(Figure 7A): AD8(197), J1Hx(197), J2Hx(197), J3Hx(197),
J3Hx(197,HT), J3Hx(197,N) and J3Hx(197,HT,N); and
5. For cold sensitivity versus the sCD4 neutralization-to-binding
ratio (Figure 9B) and for sCD4 neutralization sensitivity versus
the product of cold sensitivity and CD4-Ig binding (Figure 9C):
In addition to the standardized panel of 16 primary HIV-1
envelope glycoproteins, we included eight transmitted/founder
strains (WEAU-d15.410.787, 1006-11.C3.1601, 1056-
10.TA11.1826, 1012-11.TC21.3257, 6240.08.TA5.4622,
62357.14.D3.4589, 700010040.C9.4520, and PRB926-
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and 271-11 were also included due to their high sensitivity to
inhibition by sCD4.
Supporting Information
Figure S1 Identification and phenotypic characteriza-
tion of envelope glycoprotein changes that contribute to
the infection of CD4
2 CCR5
+ CELLS. (A) Infection of
CD4
2CCR5
+ and CD4
+CCR5
+ Cf2Th cells by luciferase-
expressing viruses that contain the indicated envelope glycopro-
teins (10,000 RT units per sample). In the upper two panels, data
are expressed as mean luciferase activity (relative light units, RLU,
6 SEM) of three replicate samples. In the bottom left panel, the
relative CD4-independent infectivity (infection of CD4
2CCR5
+
cells expressed as a percentage of infection of CD4
+ CCR5
+ cells
measured for each envelope glycoprotein construct) is presented.
In the bottom right panel, the percent maximal infection (infection
of CD4
2CCR5
+ cells mediated by each envelope glycoprotein
expressed as a percentage of maximal infection of CD4
2 CCR5+
cells measured for the virus containing the J1Hx(197) envelope
glycoproteins) is shown. This latter measure of CD4 indepen-
dence, which is unaffected by the efficiency with which the
envelope glycoproteins interact with CD4, is shown for compar-
ison because some of the correlation analyses utilized this
parameter. (B) Cell-surface immunoprecipitation of envelope
glycoproteins. COS-1 cells were transfected with the indicated
envelope glycoproteins and labeled with
35S-cysteine/methionine.
Two days after transfection, cells were incubated with the 2G12
antibody (1 mg/ml) in binding buffer (PBS containing 3% BSA) for
30 min at room temperature. Cells were then washed three times
with binding buffer and lysed using NP-40 buffer (0.5 M NaCl,
10 mM Tris, pH 7.5 and 0.5% [vol/vol] NP-40). Envelope
glycoprotein-2G12 complexes were precipitated with Protein A-
Sepharose beads and analyzed by SDS-PAGE. The envelope
glycoprotein bands on the gel were detected by PhosphorImager.
(C) Virion incorporation of envelope glycoproteins. Viruses
containing the indicated envelope glycoprotein variants were
generated and purified by ultracentrifugation through a 20%
sucrose cushion. The control viruses produced in the pcDNA-
transfected cells do not contain envelope glycoproteins. Pellets
were then resuspended in PBS and virion content determined by
reverse transcriptase (RT) activity. Samples were analyzed by
SDS-PAGE (gel loading normalized by RT activity) and Western
blotted using pooled serum obtained from HIV-1 infected
individuals. The positions of the p24 capsid protein and gp120
envelope glycoprotein are indicated. Results are representative of
those obtained in two independent experiments.
(TIF)
Figure S2 Envelope Glycoprotein binding and neutral-
ization by the trimer-specific antibody PG16. (A) Binding
of PG16 (0.2 mg/ml) to COS-1 cells expressing the indicated
envelope glycoproteins at 4uC in the absence and presence of
sCD4 (20 mg/ml). Data are presented as mean percentage of
PG16 binding (6 SEM) relative to the binding of the 2G12
antibody (2 mg/ml) to each envelope glycoprotein variant; the data
were derived from duplicate experiments. (B) Neutralization of
viruses containing the indicated envelope glycoprotein variants by
the PG16 antibody. Residual infection represents the percentage
of infection measured after incubation with the indicated
concentration of the PG16 antibody relative to that observed in
the absence of antibody. The envelope glycoproteins are color
coded according to their relative CD4-independent infectivity (see
left column in Figure 4A). Data represent the means derived from
three replicate samples.
(TIF)
Figure S3 Infection of CD4
2CCR5
+ and CD4
+CCR5
+
cells by viruses that contain a deletion of the gp120 V1/
V2 loops (DV) and/or the gp41 changes. The mean
luciferase activity (6 SEM) from an experiment performed with
three replicate samples is presented (37,500 RT units added per
well). In the bottom panel, infection of CD4
2CCR5
+ cells is
expressed as the percentage of infection of CD4
+CCR5
+ cells.
(TIF)
Figure S4 Exposure of the gp41 HR1 coiled coil on the
HIV-1 envelope glycoproteins. (A) Effect of envelope
glycoprotein cytoplasmic tail deletion on infection of
CD4
2CCR5
+ and CD4
+CCR5
+ cells. Viruses that express the
luciferase gene and contain the indicated full-length or cytoplasmic
tail-deleted (Dct) envelope glycoproteins were generated and RT
activity measured. Virus preparations were incubated with
CD4
2CCR5
+ or CD4
+CCR5
+ cells (10,000 RT units per well).
The mean luciferase activity (6 SEM) from an experiment
performed with three replicate samples is presented. (B) Effect of
temperature on binding of C34-Ig to cell surface-expressed
envelope glycoproteins. COS-1 cells transiently expressing the
indicated envelope glycoproteins were incubated with sCD4
(40 mg/ml) or buffer for 3 min at 37uC. Samples were subse-
quently washed three times to remove excess sCD4 and then
incubated with C34-Ig (40 mg/ml) for 30 min at the indicated
temperature. Binding of C34-Ig to the envelope glycoproteins is
shown in the top panel. Binding of the CD4-Ig probe (0.6 mg/ml)
after incubation for 30 min at the indicated temperature is shown
in the bottom panel. Data represent the means (6 SEM) derived
from duplicate samples. (C) Binding of C34-Ig to V1/V2 loop-
deleted envelope glycoproteins in the absence and presence of
sCD4. COS-1 cells that transiently express the indicated
cytoplasmic tail-deleted envelope glycoproteins were incubated
with C34-Ig (30 mg/ml) at 26uC for 30 min in the absence or
presence of sCD4 (20 mg/ml). Data represent mean (6 SEM)
binding values after subtraction of background values of C34-Ig
binding to mock-transfected cells. In the bottom panel, C34-Ig
binding in the absence of sCD4 is expressed as the percentage of
C34-Ig binding in the presence of sCD4. (D) Binding of C34-Ig
(40 mg/ml) to COS-1 cells expressing the indicated cytoplasmic
tail-deleted envelope glycoprotein variants at 26uC, in the absence
or presence of sCD4 (20 mg/ml). Binding of CD4-Ig (0.5 mg/ml)
was also measured (bottom panel).
(TIF)
Figure S5 Effect of envelope glycoprotein changes on
exposure and stability of the HR1 coiled coil. (A) Effect of
the H66N and S375W changes (indicated by 66 and 375,
respectively) on the capacity of envelope glycoproteins to infect
CD4
2CCR5
+ and CD4
+CCR5
+ cells (25,000 RT units per well).
(B) Effect of the H66N and S375W changes on binding of C34-Ig
(30 mg/ml) to COS-1 cells expressing the indicated cytoplasmic
tail-deleted envelope glycoprotein variants at 16uC, in the absence
or presence of sCD4 (20 mg/ml). The deletion of the gp120 V1/
V2 variable loops is indicated by DV. (C) Decay rate of exposure
of the gp41 HR1 coiled coil after pulse activation by sCD4. COS-1
cells transiently expressing the indicated envelope glycoprotein
variants were incubated with sCD4 (30 mg/ml) for 3 min at 37uC.
Cells were then washed to remove excess sCD4 and incubated for
different time periods at 37uC. The C34-Ig probe (30 mg/ml) was
subsequently incubated with the cells at 25uC. Data represent
mean (6 SEM) percentages of C34-Ig binding, relative to the
Reactivity of HIV-1 Envelope Glycoproteins
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after the sCD4 pulse and subsequent wash.
(TIF)
Figure S6 Inhibitor sensitivity of viruses containing
envelope glycoprotein variants with the N197S and gp41
changes. Residual infection represents the percentage of
infection measured following incubation of the viruses containing
the indicated envelope glycoproteins with the inhibitor, relative to
that seen in the absence of inhibitor. Color coding in A–F is based
on the relative CD4-independent infectivity of viruses with the
indicated envelope glycoproteins (see left column in Figure 4A).
(TIF)
Figure S7 Neutralization sensitivity of V1/V2 loop-
deleted envelope glycoprotein variants. (A) Relative CD4-
independent infectivity and neutralization sensitivity of viruses that
contain the indicated envelope glycoprotein variants. The
envelope glycoproteins are color coded for each phenotype as in
Figure 4A. (B–D) Neutralization of viruses with the indicated
envelope glycoproteins by sCD4 and antibodies. Each envelope
glycoprotein variant is color coded according to its relative CD4-
independent infectivity (left column, panel A).
(TIF)
Figure S8 Effect of the H66N and S375W changes on
CD4 independence and neutralization sensitivity. (A)
Infection of CD4
2CCR5
+ or CD4
+CCR5
+ cells by viruses
containing the indicated envelope glycoprotein variants (37,500
RT units per well). (B–G) Neutralization sensitivity of viruses
containing the indicated envelope glycoproteins. Residual infec-
tion represents the percentage of infection measured following
incubation of the viruses containing the indicated envelope
glycoproteins with the inhibitor, relative to that seen in the
absence of inhibitor. Color coding is based on the relative CD4-
independent infectivity of each variant (see panel A and Figure 5).
(TIF)
Figure S9 Ligand binding to cell surface-expressed
envelope glycoproteins. (A) Binding kinetics of 17b antibody
to envelope glycoprotein trimers expressed on the surface of cells.
COS-1 cells expressing the indicated envelope glycoprotein
variants were incubated with the 17b antibody (2 mg/ml) at
37uC for different time periods. Cells were then washed to remove
excess antibody and binding detected using a secondary HRP-
conjugated antibody. Data are presented as a percentage of
maximal binding measured at the last time point. Envelope
glycoproteins are color coded according to their sensitivity to
neutralization by 17b. Absolute binding values measured at the
last time point are shown in the panel on the right. (B) Effect of
inhibitor binding to envelope glycoprotein trimers on recognition
by the 412d antibody. COS-1 cells expressing the indicated
envelope glycoprotein variants were incubated for 30 min at 37uC
with JRC-II-191 (200 mM), sCD4 (400 nM), the F105 antibody
(10 mg/ml), sCD4 and C34 peptide (400 nM and 1 mM,
respectively) or the D49 antibody (10 mg/ml). Cells were then
washed three times and incubated with the 412d antibody (0.7 mg/
ml). 412d binding was detected using a preparation of HRP-
conjugated goat-anti-human IgG secondary antibodies that does
not bind to the F105 antibody or to the mouse D49 antibody. Data
represent mean binding values (6 SEM) derived from duplicate
samples. As expected, initial incubation with sCD4 or the CD4-
mimetic compound JRC-II-191 increased 412d binding, whereas
pre-incubation with the F105 antibody significantly decreased
412d binding, as previously shown (references 45,84). (C) Effect of
inhibitor binding to envelope glycoprotein trimers on recognition
by 2F5, sCD4 and 2G12. COS-1 cells expressing the indicated
envelope glycoprotein variants were incubated with the priming
antibodies F105, 17b, 2F5 or 2G12 (all at 5 mg/ml) or with sCD4
(20 mg/ml) for 30 min at 37uC. Cells were then washed three
times and incubated with sCD4 (left panel, 10 mg/ml), 2F5
antibody (middle panel, 1 mg/ml) or the 2G12 antibody (right
panel, 1 mg/ml). Binding of sCD4 was detected using the OKT4
antibody (10 mg/ml). Binding of 2F5 and 2G12 was detected using
a preparation of HRP-conjugated goat-anti-human IgG secondary
antibodies that does not bind to the F105 antibody. Data represent
mean binding values (6 SEM) derived from duplicate samples.
The finding that exposure to the inhibitor does not result in altered
antigenicity of the envelope glycoproteins suggests that inhibition
is not mediated by increased gp120 shedding,
(TIF)
Figure S10 CD4 independence and cold sensitivity of
envelope glycoproteins. (A) Sensitivity of the indicated envelope
glycoprotein variants to cold-induced inactivation. The level of
infection of CD4
+CCR5
+ cells by viruses with the indicated
envelope glycoproteins following incubation on ice for the times
shown was divided by the level of infection seen for freshly thawed
viruses to yield the residual infection. Data represent mean levels of
infection (6 SEM) derived from three replicate samples. (B) Effect
of the S375W change in gp120 on cold sensitivity of viruses
containing the indicated envelope glycoproteins. Cold sensitivity
wasmeasured asin(A). Data representmeanpercentagesofresidual
infection (6 SEM) derived from three replicate samples. (C) Effect
of the CD4-mimetic compound JRC-II-191 on cold sensitivity.
Viruses containing the indicated envelope glycoprotein variants
were incubated for different time periods on ice in the absence or
presence of JRC-II-191 (20 mM). Samples were then added to
CD4
+CCR5
+ cells and infectivity was measured 2 days later.
Residual infection represents the level of infection, relative to that
observed for viruses not incubated on ice. (D) Comparison of the
cold sensitivity of viruses containing full-length and cytoplasmic tail-
deleted (Dct) envelope glycoproteins. In the left column, the relative
level of CD4-independent infectivity of the full-length variants is
indicated. Values are color coded according to the rank order of the
measured phenotype. (E) Virus capture assay to measure the
presence of gp120 on virions. Viruses that contain both the
indicated full-length envelope glycoprotein variants and the
vesicular stomatitis virus G protein were incubated for different
time periods on ice and then captured on a plate coated with the
2G12 antibody. The amount of virus captured was assessed by
measuring infectivity on CD4
2CCR5
2 Cf2Th cells. A detailed
description of the method is providedinthe Materialsand Methods.
Data represent the mean values (6 SEM) derived from three
replicate samples. The envelope glycoprotein variants are color
coded according to their relative level of cold sensitivity. (F) Cold-
induced shedding of gp120. Purified virus preparations containing
the indicated envelope glycoproteins were incubated for different
lengths of time on ice and then virions were pelleted again. Proteins
in the pellet and supernatant were separated by SDS-PAGE and
Western blotted. The Western blots were probed with serum
derived from HIV-1-infected individuals and quantitated by
densitometry. Data represent the intensity of the gp120 band in
the supernatant at each time point, relative to that measured for
samples not incubated on ice. The amount of gp120 in samples not
incubated on ice, corrected for virion content by RT activity, is
shown in the bottompanel. No significantdifferenceswereobserved
in the gp120 content of the pelleted virions (data not shown). The
envelope glycoproteins are color coded according to their relative
level of cold sensitivity.
(TIF)
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panel of 16 envelope glycoproteins from primary HIV-1
isolates. Data were obtained from a registry of molecularly cloned
HIV-1, SIV and SHIV envelope glycoproteins that can be used to
pseudotype HIV-1 in neutralizing antibody assays; the registry was
compiled by the Laboratory for AIDS Vaccine Research &
Development, Duke University Medical Center and is available at
http://www.hiv.lanl.gov/content/nab-reference-strains/html/home.
htm). Data are presented as the concentration of inhibitor at which
virus infectivity was reduced by 50% relative to cultures without
added inhibitor. The two-tailed T-test P values for the comparison
between the IC50 v a l u e sf o rT i e r1a n dT i e r2e n v e l o p eg l y c o p r o t e i n s
are indicated.
(TIF)
Figure S12 The neutralization-to-Binding Ratio as a
measure of envelope glycoprotein reactivity to inhibitor
binding. (A–D) Neutralization-to binding ratios for the four
inhibitors. Binding of the inhibitors to cell surface-expressed
envelope glycoproteins was measured by cell-based ELISA and
normalized for cell-surface expression measured by cell-surface
immunoprecipitation. Data are expressed as the reciprocal of the
IC50 value of each envelope glycoprotein strain divided by the
normalized binding efficiency. The envelope glycoproteins are
colored according to neutralization sensitivity (Tier 1A, black; Tier
1B, grey; and Tier 2, empty bars). The P value for the two-tailed
T-Test performed to compare the neutralization-to-binding ratios
between Tier 1 and Tier 2 envelope glycoproteins is shown.
(TIF)
Figure S13 Relationship between cold sensitivity and
inhibitor reactivity. (A) The relationship between the cold
sensitivity of viruses containing envelope glycoproteins from the
standardized panel of 16 primary HIV-1 isolates and the average
neutralization-to-binding index for the four inhibitors (see
Figure 8B) is shown. (B–E) The relationship between cold
sensitivity and reactivity to the binding of the indicated inhibitors
is shown. The neutralization-to-binding ratio is defined as the
reciprocal of the IC50 value of virus containing that envelope
glycoprotein divided by the normalized binding efficiency of the
inhibitor to the cell surface-expressed envelope glycoproteins. The
Spearman rank-order correlation coefficient is indicated (*,
P,0.05).
(TIF)
Table S1 Effect of cytoplasmic tail deletion on binding
of CD4-induced antibodies to the envelope glycopro-
teins.
(TIF)
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